Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Emory University · Cancer Institute (WIA) · +29 more institutions
Abstract
Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma.
In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival.
Citation impact
- FWCI
- 112.13
- Percentile
- 100%
- References
- 15
Authors
28- SLSagar LonialCorresponding
Emory University, Cancer Institute (WIA), Piedmont Reference Center for Epidemiology and Cancer Prevention
- MΑMeletios Α. Dimopoulos
National and Kapodistrian University of Athens
- APAntonio Palumbo
Azienda Ospedaliero Universitaria San Giovanni Battista
- DWDarrell White
Dalhousie University
- SGSebastian Grosicki
Medical University of Silesia
Topics & keywords
- Lenalidomide
- Medicine
- Internal medicine
- Multiple myeloma
- Progression-free survival
- Oncology
- Neutropenia
- Hazard ratio
- Good health and well-being